Leader™ Low Dose Aspirin provides a 4-month supply of 81 mg enteric-coated tablets for sustained cardiovascular protection under medical supervision. The physician-recommended dosage supports platelet aggregation inhibition, reducing thrombotic risk in primary and secondary prevention protocols for heart attack and stroke. The enteric coating technology ensures gastric bypass, allowing dissolution in the small intestine where absorption occurs, thereby minimizing gastrointestinal irritation and ulceration risk associated with chronic aspirin use. The 120-tablet format offers exceptional value and convenience for long-term daily therapy compliance. Ideal for individuals following evidence-based aspirin regimens for cardiovascular disease prevention, this formulation balances therapeutic efficacy with gastrointestinal tolerability for sustained adherence to physician-directed treatment protocols.